



**2017 Alliance Fall Group Meeting**  
Loews Chicago O'Hare Hotel – Rosemont, IL  
November 3<sup>rd</sup> 2017  
4:00 pm- 7:00 pm

## **Respiratory Committee Meeting Agenda**

Chair(s): Tom Stinchcombe, M.D.

Vice-Chairs: Dennis Wigle (Surgery), Steven Schild (Radiation Oncology), and Stephen Graziano (Correlative Science)

### Agenda Items

#### **1. Committee overview and protocol accrual – Chair and Xiaofei Wang**

➤ **Update Alliance Foundation: David Kozono**

➤ **Patient advocate: Pam Moffitt**

➤ **Intergroup trials**

1. NRG LU002: Pranshu Mohindra

2. EA5152: Muhammad Furqan

3. S1507: Jimmy Ruiz

#### **2. Stage IV Non-Small Cell Lung Cancer**

➤ **A221504 - Peripheral Opioid Receptor Antagonist in NSCLC – Pankaj Gupta,**

**Lyudmila Bazhenova**

➤ **S-1400 SWOG Squamous Master Protocol in Alliance– Lyudmila**

**Bazhenova, Tom Stinchcombe**

➤ **ALK Master protocol**

➤ **AFT-09: Chemo-Immunotherapy Sequencing – Tom Hensing**

➤ **AFT-31: Nivolumab +/- abraxane as second line therapy – Neal Ready**

➤ **AFT-42: Nivolumab for patients with compromised organ function – Becca Heist, Phil Stella**

**4. Stage III Non-Small Cell Lung Cancer and Radiation Oncology trials update-  
Steven Schild**

- **A-31101, RTOG 1306:** Personalized therapy for inoperable stage III NSCLC -  
**Ramaswamy Govindan**
- **ATF-07:** Chemoradiation plus veliparib –**Tom Stinchcombe**
- **AFT-16:** Induction PDL-1 inhibition – **Helen Ross, Jim Urbanic, David  
Carbone**

**5. Early Stage Non-Small Cell Lung Cancer and Surgical Studies- Dennis Wigle**

- **CALGB 140503:** Lobectomy vs. limited resection – **Nasser Altorki**
- **A151216/081105- ALCHEMIST-** Personalized Adjuvant Therapy in Patients  
with Completely Resected Non-Small Cell Lung Cancer – **Geoffrey Oxnard,  
Ramaswamy Govindan, Dennis Wigle, Sumithra Mandrekar**
- **Chemo-immunotherapy for operable stage III NSCLC** Linda Martin

**6. Small Cell Lung Cancer**

- **CALGB 30610:** Limited Stage Intergroup Trial– **Jeffrey Bogart and Greg  
Masters**
- **SWOG PCI protocol** Jyoti Patel
- **Limited stage SCLC ChemoRT +/- atezolizumab concept discussion –  
Helen Ross**
- **AFT-17: Pembrolizumab vs topotecan for 2nd line SCLC and update on  
immuno-therapies in SCLC – Tom Stinchcombe**

**7. Correlative Science- Robert Kratzke, Stephen Graziano**

- **Overview of current projects**

**8. Mesothelioma–Robert Kratzke, Hedy Kindler, Arkadiusz Dudek**

➤ **Joint Alliance SWOG concept:** Pembrolizumab in second-line therapy – **Hedy Kindler**

➤ **Other updates – Hedy Kindler, Robert Kratzke**

**9. Ongoing projects from other committees**

➤ **CANVAS (AFT-28)-** Deborah Schrag

➤ **Effect of age and performance status on chemotherapy toxicity over time in patients with advanced non-small cell lung cancer: A Toxicity over Time analysis of CALGB 9730** Melissa Wong

➤ **NCI's Quantitative Imaging Network U01-**Lawrence Schwartz